



Press release

Ad-hoc announcement pursuant to Art. 53 LR

SHL announces invitation to a Special General Meeting

Tel Aviv / Zurich, July 4, 2022 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) (“**SHL**” or the “**Company**”), a leading provider and developer of advanced personal telemedicine solutions, today announces that a Special General Meeting (SGM) of the Shareholders of the Company will be held on **August 11, 2022, at 13:00** (Israel Time), at the Company’s registered office, located at 90 Yigal Alon Street, Ashdar Building, Tel Aviv, Israel.

The agenda shall include the following matters:

1. Amendment to Article 40 of the Articles of Association of the Company, so that the Board of Directors (the “Board”) may elect more than one of its members to be the chairmen of the Board.
2. Following the approval of the Compensation Committee and of the Board – the approval of amendments to the current Compensation Policy of the Company. For further details see the Notice to Shareholders available on the Company website: <https://www.shl-telemedicine.com/general-meeting/>
3. Following the approval of the Compensation Committee and of the Board and subject to the approval of items 1 and 2 on the agenda – the approval of the terms of office of the to be appointed Co-Chairman of the Board, the former Israeli Prime Minister, Mr. Ehud Barak. The terms include compensation of a fixed monthly fee as well as bonuses related to commercial agreements and strategic transaction. For further details see the Notice to Shareholders available on the Company website: <https://www.shl-telemedicine.com/general-meeting/>
4. Following the approval of the Compensation Committee and of the Board - the approval of amendments to the services agreement of the CEO of the Company. For further details see the Notice to Shareholders available on the Company website: <https://www.shl-telemedicine.com/general-meeting/>
5. Following the approval of the Compensation Committee and of the Board - the approval of grant of a letter of exemption to the Company’s officers and directors.

All of the above as more fully set forth in the Notice to Shareholders available on the Company website.

The record date was set for **August 2, 2022**.

One or more shareholders holding shares representing at least one percent (1%) of the voting rights at the General Meeting may request the Board, in writing, not later than seven (7) days from the date of the invitation to the Special General Meeting, to include an item on the agenda of the Special General Meeting to be held. Such item shall be included on the Special General Meeting’s agenda, provided that the Board found it to be suitable for discussion at the Special General Meeting. Should there be any changes in the agenda of the Special General Meeting due to such shareholder’s request, amended Notice shall be available on the Company’s website at <https://www.shl-telemedicine.com/general-meeting/>



not later than fourteen (14) days from the date of the invitation to the Special General Meeting.

The invitation to the SGM shall not be published in newspapers. The full invitation to the SGM can be downloaded on <https://www.shl-telemedicine.com/general-meeting/>.

For further information please contact:

Fabienne Farner, IRF, Phone: +41 43 244 81 42 farner@irf-reputation.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.